{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Ezetimibe%29&page=2", "query": { "intervention": "Placebo (for Ezetimibe)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Ezetimibe%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+%28for+Ezetimibe%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T07:58:58.080Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00477204", "title": "Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus", "Dyslipidemia" ], "interventions": [ { "name": "Simvastatin", "type": "DRUG" }, { "name": "Ezetimibe/Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "12 Years to 18 Years" }, "enrollment_count": 9, "start_date": "2007-05", "completion_date": "2010-08", "has_results": true, "last_update_posted_date": "2020-11-10", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00477204" }, { "nct_id": "NCT01730040", "title": "Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 355, "start_date": "2012-10", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2015-08-31", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 56, "location_summary": "Mobile, Alabama • Chandler, Arizona • Tucson, Arizona + 53 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730040" }, { "nct_id": "NCT01984424", "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Placebo to Atorvastatin", "type": "DRUG" }, { "name": "Placebo to Ezetimibe", "type": "OTHER" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "OTHER" }, { "name": "Evolocumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 511, "start_date": "2013-12-10", "completion_date": "2017-11-21", "has_results": true, "last_update_posted_date": "2018-11-29", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 18, "location_summary": "Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 15 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Pedro", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984424" }, { "nct_id": "NCT01644474", "title": "Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Patients With Hypercholesterolemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Alirocumab", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo (for Alirocumab)", "type": "DRUG" }, { "name": "Placebo (for Ezetimibe)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2012-07", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2015-11-06", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 3, "location_summary": "Overland Park, Kansas • Cincinnati, Ohio • Richmond, Virginia", "locations": [ { "city": "Overland Park", "state": "Kansas" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01644474" }, { "nct_id": "NCT01375777", "title": "Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hyperlipidemia" ], "interventions": [ { "name": "Evolocumab", "type": "BIOLOGICAL" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebo to Evolocumab", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 411, "start_date": "2011-07-06", "completion_date": "2012-03-02", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Encinitas", "state": "California" }, { "city": "Inglewood", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01375777" }, { "nct_id": "NCT01047501", "title": "Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertriglyceridemia" ], "interventions": [ { "name": "AMR101 (ethyl icosapentate) - 4 g/day", "type": "DRUG" }, { "name": "AMR101 (ethyl icosapentate) - 2 g/day", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amarin Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 702, "start_date": "2009-12", "completion_date": "2011-02", "has_results": true, "last_update_posted_date": "2022-04-25", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 80, "location_summary": "Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Scottsboro", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01047501" }, { "nct_id": "NCT05763875", "title": "Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Inclisiran", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Matching Placebo for Inclisiran", "type": "DRUG" }, { "name": "Matching Placebo for Ezetimibe", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 350, "start_date": "2023-03-15", "completion_date": "2024-06-20", "has_results": true, "last_update_posted_date": "2025-10-16", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "DeLand", "state": "Florida" }, { "city": "Maitland", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05763875" }, { "nct_id": "NCT00127218", "title": "High-Density Lipoprotein (HDL) Cholesterol Increased Plaque Stabilization in the Elderly", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atherosclerosis", "Cardiovascular Disease" ], "interventions": [ { "name": "any statin", "type": "DRUG" }, { "name": "niacin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 145, "start_date": "2003-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2017-11-06", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00127218" }, { "nct_id": "NCT03337308", "title": "A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hyperlipidemias" ], "interventions": [ { "name": "Bempedoic Acid + Ezetimibe Fixed-Dose Combination", "type": "COMBINATION_PRODUCT" }, { "name": "Bempedoic Acid", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Placebos", "type": "DRUG" } ], "intervention_types": [ "COMBINATION_PRODUCT", "DRUG" ], "sponsor": "Esperion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 382, "start_date": "2017-10-23", "completion_date": "2018-07-18", "has_results": true, "last_update_posted_date": "2020-04-08", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 5, "location_summary": "Ames, Iowa • Nashua, New Hampshire • Statesville, North Carolina + 2 more", "locations": [ { "city": "Ames", "state": "Iowa" }, { "city": "Nashua", "state": "New Hampshire" }, { "city": "Statesville", "state": "North Carolina" }, { "city": "Wilmington", "state": "North Carolina" }, { "city": "Knoxville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03337308" }, { "nct_id": "NCT01420328", "title": "To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Inflammation" ], "interventions": [ { "name": "Vytorin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2011-05-01", "completion_date": "2016-07-01", "has_results": true, "last_update_posted_date": "2024-04-17", "last_synced_at": "2026-10-06T07:58:58.080Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01420328" } ] }